Age-Specific Pharmacotherapy Considerations in Older-Age Bipolar Disorder

This narrative review synthesizes diagnostic and pharmacologic considerations for bipolar disorder in older adults, an understudied population where standard evidence is largely extrapolated from younger cohorts.

lithiumvalproatelamotriginequetiapinearipiprazoleatypical antipsychoticsmood stabilizersbipolar disorderolder adultsgeriatric psychiatryGLP-1 receptor agonistsdeprescribingnarrative review Geriatrics / Geriatric Pharmacy

Background Information

Bipolar disorder in older adults demands unique pharmacotherapy approaches.

Bipolar disorder in older adults often presents atypically, complicating diagnosis and requiring age-specific pharmacotherapy considerations due to altered pharmacokinetics and increased risk of drug interactions. Mood stabilizers and atypical antipsychotics are used, but their use in older adults needs careful monitoring due to polypharmacy and comorbidities. While LOBD and EOBD subgroups exist, pharmacologic management is similar; the study emphasizes a need for age-specific trials to improve outcomes. Managing bipolar disorder in older adults requires careful pharmacotherapy, considering age-specific challenges.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Asir B, Al-Soleiti M, Singh B

Citation: Asir B, Al-Soleiti M, Singh B Bipolar Disorder in Older Adults: A Comprehensive Overview of Pharmacotherapy Patterns and Clinical Considerations. Drugs & aging. 2026;43(8):707-720. doi:10.1007/s40266-026-01315-8

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →